Nemysis Ltd announced today the appointment of Dr. Alessio Fasano to its Scientific Advisory Board (SAB)

Nemysis Limited announces the issuance of a Canadian Patent for E40, a novel endoprotease for treatment and management of Celiac Disease and Gluten Intolerance.

Nemysis Limited, the Dublin based pharmaceutical and healthcare Company, focused on Iron Deficiency/Anemia and Gluten Sensitivity, today announced that the South Africa Patent and Trademark Office on issued S.A. Patent No.ZA201802192, with claims of Methods for Producing Carboxylate Ligand Modified Ferric Iron Hydroxide Colloids and Related Compositions and Uses, directed to the use of oral iron supplementation.

Adds 4 trademarks - Nutrafer™, Dietofer™ and IDAXTM in Iron Deficiency and TolPlus™ in Gluten Intolerance